Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer
- 244 Downloads
To assess the impact of location versus number of extra-pulmonary metastatic sites (EPMS) on survival in stage IV non-small cell lung cancer (NSCLC).
Methods and materials
Retrospective analysis was conducted on patients diagnosed during 1999–2013 with stage IV, M1b (AJCC 7th edition) NSCLC using the large, institutional Glans-Look Database, which contains patient demographic, clinical, pathological, treatment, and outcome information. We assessed the impact of location and number of EPMS and identified correlates of overall survival using the Kaplan–Meier method and Cox regression.
We identified a total of 2065 NSCLC patients with EPMS. Median age was 67 (IQR 58–75) years, 52% were men, and 78% were current or former smokers. 60% had one EPMS, and 40% had two or more EPMS. Among those with only one EPMS, most frequent organ involvement included bone (40%), brain (32%), and liver (13%). Median overall survival (mOS) was worst in those with liver metastasis and best in those with adrenal metastasis (2.0 vs. 5.2 months, p = 0.015). However, outcomes based on site of organ involvement were not significantly different in multivariable analysis. Compared to patients with one EPMS, individuals with two or more EPMS experienced worse outcomes (mOS ≤ 2.9 vs. 3.9 months, p < 0.001), and were associated with worse prognosis in Cox regression analysis (HR 1.5, 95% CI 1.3–1.7, p < 0.001).
Number rather than location of EPMS is a prognostic factor in patients with stage IV M1b NSCLC. This information is relevant for accurate prognostication, stratification of participants in future clinical trials, and timely and appropriate advanced care planning.
KeywordsNon-small cell lung cancer Survival Distant disease Extra-pulmonary metastases Disease burden Metastatic site Number of metastases
- 1.Canadian Cancer Statistics 2017. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Toronto: Canadian Cancer Society; 2017. http://www.cancer.ca/Canadian-CancerStatistics-2017-EN.pdf. Accessed 28 Aug 2017.
- 5.Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(suppl 5):e341S–358S. https://doi.org/10.1378/chest.12-236.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Non-small cell. lung cancer survival rates, by stage. American Cancer Society. http://cancer.org/cancer/lungcancer-non-smallcell/detailedhuide/non-small-cell-lung-cancer-survival-rates. Published May 16, 2016. Accessed 28 Aug 2017.
- 8.Dias M, Coutinho D, Linhas R, et al. Non-small lung cancer: are M1a and M1b the same Stage? Eur Respir J. 2015; 46(suppl 59): PA4288. https://doi.org/10.1183/13993003.congress-2015.PA4288.CrossRefGoogle Scholar
- 11.R: A language and environment for statistical computing [computer program]. Version 3.3.0. Vienna, Austria. R Foundation for Statistical Computing, R Core Team; 2016. https://www.R-project.org.
- 15.Bates J, Milano M. Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. J Thorac Dis. 2017;9(7):1903–10. http://jtd.amegroups.com/article/view/14548.
- 16.Eberhardt WEE, Mitchell A, Crowley, et al. The IASLC lung cancer staging project: proposals for the revision of the m descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(11):1515–22. https://doi.org/10.1097/JTO/000000000000673.CrossRefPubMedGoogle Scholar
- 23.Park JH, Kim TM, Keam B, et al. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive getfitinib. Clin Lung Cancer. 2013;14(4):383–9. https://doi.org/10.1016/j.cllc.2012.10.007.CrossRefPubMedGoogle Scholar
- 31.Iyengar P, Lau S, Donington JS, Suh RD. Local therapy for limited metastatic non-small cell lung cancer: what are the options and is there a benefit? Presentation at: ASCO Annual Meeting; June 6, 2016; Chicago.Google Scholar